287 related articles for article (PubMed ID: 34878295)
21. Sialic acids siglec interaction: a unique strategy to circumvent innate immune response by pathogens.
Khatua B; Roy S; Mandal C
Indian J Med Res; 2013 Nov; 138(5):648-62. PubMed ID: 24434319
[TBL] [Abstract][Full Text] [Related]
22. Separate pathways for O acetylation of polymeric and monomeric sialic acids and identification of sialyl O-acetyl esterase in Escherichia coli K1.
Steenbergen SM; Lee YC; Vann WF; Vionnet J; Wright LF; Vimr ER
J Bacteriol; 2006 Sep; 188(17):6195-206. PubMed ID: 16923886
[TBL] [Abstract][Full Text] [Related]
23. Escherichia coli in bacteremia: O-acetylated K1 strains appear to be more virulent than non-O-acetylated K1 strains.
Frasa H; Procee J; Torensma R; Verbruggen A; Algra A; Rozenberg-Arska M; Kraaijeveld K; Verhoef J
J Clin Microbiol; 1993 Dec; 31(12):3174-8. PubMed ID: 7508454
[TBL] [Abstract][Full Text] [Related]
24. Sialic Acid-Siglec-E Interactions During
Mukherjee K; Khatua B; Mandal C
Front Immunol; 2020; 11():332. PubMed ID: 32184783
[No Abstract] [Full Text] [Related]
25. Discovery and expression of 3 siglecs-like in Oreochromis niloticus neutrophil, and their interaction with group B streptococcal sialylated capsular polysaccharides.
Dong J; Wei Y; Ye X; Sun C; Tian Y; Lu M; Du J; Chen Z
Mol Immunol; 2016 May; 73():158-69. PubMed ID: 26847490
[TBL] [Abstract][Full Text] [Related]
26. Functional relationships of the sialyltransferases involved in expression of the polysialic acid capsules of Escherichia coli K1 and K92 and Neisseria meningitidis groups B or C.
Steenbergen SM; Vimr ER
J Biol Chem; 2003 Apr; 278(17):15349-59. PubMed ID: 12578835
[TBL] [Abstract][Full Text] [Related]
27. Relative opsonic and protective activities of antibodies against K1, O and lipid A antigens of Escherichia coli.
Welch WD; Martin WJ; Stevens P; Young LS
Scand J Infect Dis; 1979; 11(4):291-301. PubMed ID: 93778
[TBL] [Abstract][Full Text] [Related]
28. Preclinical validation of an
Chorro L; Ndreu D; Patel A; Kodali S; Li Z; Keeney D; Dutta K; Sasmal A; Illenberger A; Torres CL; Pan R; Silmon de Monerri NC; Chu L; Simon R; Anderson AS; Donald RGK
Microbiol Spectr; 2024 Jun; 12(6):e0421323. PubMed ID: 38700324
[TBL] [Abstract][Full Text] [Related]
29. Selective synthesis and labeling of the polysialic acid capsule in Escherichia coli K1 strains with mutations in nanA and neuB.
Vimr ER
J Bacteriol; 1992 Oct; 174(19):6191-7. PubMed ID: 1400168
[TBL] [Abstract][Full Text] [Related]
30. Exploring the Impact of Ketodeoxynonulosonic Acid in Host-Pathogen Interactions Using Uptake and Surface Display by Nontypeable Haemophilus influenzae.
Saha S; Coady A; Sasmal A; Kawanishi K; Choudhury B; Yu H; Sorensen RU; Inostroza J; Schoenhofen IC; Chen X; Münster-Kühnel A; Sato C; Kitajima K; Ram S; Nizet V; Varki A
mBio; 2021 Jan; 12(1):. PubMed ID: 33468699
[TBL] [Abstract][Full Text] [Related]
31. Evolution of CD33-related siglecs: regulating host immune functions and escaping pathogen exploitation?
Cao H; Crocker PR
Immunology; 2011 Jan; 132(1):18-26. PubMed ID: 21070233
[TBL] [Abstract][Full Text] [Related]
32. A review: relation between invasiveness and the K1 capsular polysaccharide of Escherichia coli.
Schiffer MS; Oliveira E; Glode MP; McCracken GH; Sarff LM; Robbins JB
Pediatr Res; 1976 Feb; 10(2):82-7. PubMed ID: 1107953
[TBL] [Abstract][Full Text] [Related]
33. Are antibodies to the capsular polysaccharide of Neisseria meningitidis group B and Escherichia coli K1 associated with immunopathology?
Stein DM; Robbins J; Miller MA; Lin FY; Schneerson R
Vaccine; 2006 Jan; 24(3):221-8. PubMed ID: 16125824
[TBL] [Abstract][Full Text] [Related]
34. Monoclonal antibodies specific for the phase-variant O-acetylated K1 capsule of Escherichia coli.
Torensma R; van Wijk A; Visser MJ; Bouter A; Rozenberg-Arska M; Verhoef J
J Clin Microbiol; 1991 Jul; 29(7):1356-8. PubMed ID: 1885731
[TBL] [Abstract][Full Text] [Related]
35. Constitutively expressed Siglec-9 inhibits LPS-induced CCR7, but enhances IL-4-induced CD200R expression in human macrophages.
Higuchi H; Shoji T; Iijima S; Nishijima K
Biosci Biotechnol Biochem; 2016 Jun; 80(6):1141-8. PubMed ID: 26923638
[TBL] [Abstract][Full Text] [Related]
36. The capsule supports survival but not traversal of Escherichia coli K1 across the blood-brain barrier.
Hoffman JA; Wass C; Stins MF; Kim KS
Infect Immun; 1999 Jul; 67(7):3566-70. PubMed ID: 10377140
[TBL] [Abstract][Full Text] [Related]
37. The immunobiology of Campylobacter jejuni: Innate immunity and autoimmune diseases.
Phongsisay V
Immunobiology; 2016 Apr; 221(4):535-43. PubMed ID: 26709064
[TBL] [Abstract][Full Text] [Related]
38. Siglec-G/10 in self-nonself discrimination of innate and adaptive immunity.
Chen GY; Brown NK; Zheng P; Liu Y
Glycobiology; 2014 Sep; 24(9):800-6. PubMed ID: 24996822
[TBL] [Abstract][Full Text] [Related]
39. Escherichia coli O-antigen capsule (group 4) is essential for serum resistance.
Biran D; Rosenshine I; Ron EZ
Res Microbiol; 2020 Mar; 171(2):99-101. PubMed ID: 31982499
[TBL] [Abstract][Full Text] [Related]
40. Polysialic acid and Siglec-E orchestrate negative feedback regulation of microglia activation.
Thiesler H; Beimdiek J; Hildebrandt H
Cell Mol Life Sci; 2021 Feb; 78(4):1637-1653. PubMed ID: 32725371
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
